Managing Patients With AF Undergoing PCI: What Are the Data and Real-World Implications?

Professor Keith AA Fox is Duke of Edinburgh Professor of Cardiology at the University of Edinburgh.

Previous posts included Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, St Louis, USA; Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff; Head of Division of Medical and Radiological Sciences of the University of Edinburgh; British Heart Foundation Professor of Cardiology and Consultant Cardiologist in the Royal Infirmary of Edinburgh.

His awards include the Silver Medal of the European Society of Cardiology (ESC) in 2010 and again in 2014 and the Mackenzie medal of the British Cardiovascular Society in 2013. He gave the American Heart Association (AHA) “Paul Dudley White Lecture” at the AHA Congress in 2015 and was awarded the Gold Medal of the ESC in 2015.

Professor Fox’s major research interest is in the mechanisms and manifestation of acute coronary arterial disease and the work extends from underlying biological mechanisms to in-vitro and in-vivo studies and clinical trials. He is the author of more than 460 scientific papers. He is chair of the RITA studies, Co-Chairman of the Global Registry of Acute Coronary Events (GRACE) Programme and Co-Chairman of the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) studies of Clopidogrel in unstable angina/NSTEMI and other settings. Professor Fox was a lead investigator for studies on novel anti-thrombins. The GRACE Programme is the largest international programme in acute coronary disease. It runs across 14 countries and aims to define patients with acute coronary disease, to understand the time course and the disease process and to raise questions for testing in randomised trials and in basic science.

Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology.

In 2004, Dr Angiolillo joined the University of Florida College of Medicine in Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program. 

Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine.

Dr Dominick Angiolillo is on the Editorial Board of European Cardiology Review.